Xencor (NASDAQ:XNCR – Get Free Report)‘s stock had its “outperform” rating reiterated by equities researchers at Wedbush in a research note issued on Thursday, RTT News reports. They presently have a $34.00 target price on the biopharmaceutical company’s stock, down from their prior target price of $36.00. Wedbush’s price objective points to a potential upside […]